SEXBRANE Stock Latest News
Company AnnouncementsXbrane Builds Biosimilars Momentum with FDA Nod and Growing European Sales2d ago
Company AnnouncementsXbrane Wins FDA Nod for Lucamzi Biosimilar to Lucentis4d ago
Company AnnouncementsXbrane Biopharma to Present Q3 2026 Interim Results Amid Biosimilar Expansion1w ago
Company AnnouncementsXbrane Reaches Key Milestone as Xdivane Pivotal Trial Fully Enrolls Melanoma Patients2w ago
Company AnnouncementsXbrane Biopharma Sets Nomination Committee Ahead of 2027 AGM3w ago
Company AnnouncementsXbrane bolsters biosimilar pipeline as Ximluci drives revenue and FDA review advances3M agoCompany AnnouncementsXbrane and JOINN Forge Partnership to Advance Darzalex Biosimilar Xdarzane4M ago
- Company AnnouncementsXbrane Biopharma AGM Backs Board, Extends Capital-Raising Mandate5M ago
Company AnnouncementsXbrane Narrows Focus on Biosimilar Push as Q1 Loss Widens but Funding Outlook Improves6M ago- Company AnnouncementsXbrane and Intas Revise Financing Terms for Opdivo Biosimilar Xdivane6M ago
Company AnnouncementsXbrane Secures SEK 4.4bn Valuation for Xdivane Nivolumab Biosimilar Program6M ago
Company AnnouncementsXbrane Resubmits Ranibizumab Biosimilar Application to U.S. FDA6M agoCompany AnnouncementsXbrane Sets April–May Target to Resubmit Ranibizumab Biosimilar BLA to U.S. FDA7M ago
- Company AnnouncementsXbrane Swings to Profit as Ximluci Grows and Biosimilar Pipeline Advances8M ago
- Company AnnouncementsXbrane Biopharma Sets February 20 Teleconference to Present 2025 Year-End Results8M ago
Company AnnouncementsXbrane Biopharma Issues Warrants to Secure Financing Amid FDA Approval Delay11M ago
Company AnnouncementsXbrane Biopharma to Re-submit Ranibizumab Biosimilar Application to FDA11M ago
Company AnnouncementsXbrane Biopharma Advances Xdivane Clinical Trial with First Patient Inclusion12M ago